medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2002, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2002; 11 (1)

Comparison about 4 allergens extracts diagnosing hipersensitivity type in children with allergic rhinithis in the him FG

Paez BYL, Río NBE, Lerma OL, Sienra MJJL

Language: Spanish
References: 19
Page: 16-20
PDF size: 243.84 Kb.


ABSTRACT

Background: The allerge rhinitis is an inflammatory disease of the nasal mucosa whose world prevalency is high there are reports that had increased in the last decades although it is not a mortal illness, it produces an important deterioration in the quality of the boy’s life, thats why the clinical and etiologic diagnosing becomes necessary to provide and effective treatment that makes tolerance for the environment, the quality of the allergenic extract is a fundamental tool for the allergist. In Mexico there are different allergenic extracts, thats why we consider very important to determine the hypersensitivity type I from 4 available brands in our marketing.
Objective: To compare of positivity, and agreement in frequency about 4 allergens extracts from 4 available brands in children with allergenic rhinitis.
Methods: A transverse, observational, comparative and double blind assay. There where 62 children with allergic rhinitis patients from our hospital. We perform skin Prick test to: dermatophagoides, cockroach fraxinus, cat, making accurate measure from the size of the wheal. We perform reliability and positivy test in accordance of opinion of Aas, in order to investigate which in the best brand.
Statistical methods: To used positivity test, DS, y concordance test, central tendency measurement’s.
Results: Descriptive analysis, there were a total of 62 children whose ages are between 6 to 16 years with an 9.5 year-old average and a standard deviation of 2.50. The gender were 69.35% male and 30.65% female. About allergens: 1. Positive reaction to house dust mite of 41.93% group A, 20.97% group B, 14.52% group C, 17.75% group D. 2. Positive reaction to cockroach: 22.58% group A, 14.51% group B, 4.84% group C and 3.23% group D. Positive reaction to fraxinus: 16.13% group A, 9.68% group B, 0.0% group C and 3.23 group D. 4. Positive reaction to cat: 11.29% group A, 14.52% group B, 0.0% group C and 4.84 group D. Conclusions: 1. The values of the Kappa test were all smaller than 0.50 that it means the inadequate values, the agreement among the laboratories (brands) is owed random. 2. About the positivity test we concluded that the laboratory A (brand A) is the best.


REFERENCES

  1. Jacobsen L. Immunotherapy with partially purified and standardized three pollen extracts. IV Results from long-term (6 years) follow-up. Allergy 1997; 52(9): 914-20.

  2. Hejjaoui A, Dhivert H. Immunotherapy with a standardized dermatophagoides extract. IV Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 199; 85(2): 473-9.

  3. Pichler CE. Three years of specific immunotherapy with house dust mite extracts in patients with rhinitis: significant improvement of allergen specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56(4): 301-6.

  4. Ohashi Y, Nakai Y. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized extracts. Acta Otoryngol 1998; 538: 113-7.

  5. Sin B, Misirligil Z. Effect of allergen specific immunotherapy on natural killer cell activity IgE, INF-gamma, levels and clinical response in patient with allergic rhinitis and asthma. J Investig Allergol Clin Immunol 1996; (6): 341-7.

  6. Nelson HS. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000; (1 pt 1): 41-5.

  7. Cuesta-Herranz J, Lázaro M. A method for quantitation of biological activity: results in allergens extracts. J Allergy Clin Immunol 1998; 102(2): 275-80.

  8. Niinimaki A, Hannuksela M. Skin´s Prick test in vitro immunoassays. Ann Allergy Asthma Immunol 1995; 75(3): 280-6.

  9. Corsico R, Cinti B. Prevalence of sensitization to fraxinus in allergic patient in Italy. Ann Allergy Asthma Immunol 1998; 80(1): 71-6.

  10. Bowton DL, Fassano UB. Skin sensivity to allergen does not accurately predict airway response to allergen. Ann Allergy Asthma Immunol 1998; 80: 207-11.

  11. Naclerio RM, Adkinson NF. The use of standardized allergen extracts. J Allergy Clin Immunol 1997; 100(4): 505-10.

  12. Helm RM, MB. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 1985; 73: 790-800.

  13. Hejjaoui A, Dhiver M. Immunotherapy with standardized Dermatophagoides pteronyssinus extract. J Allergy Clin Immunol 1990; 45: 142-50.

  14. Turkeltaub PC. Biological standardization of allergenics extracts. Allergol Immunopathol 1989; 17(2): 53-65.

  15. Lehrer SB, Salvaggio JE. Allergens: standardization and impact of biotechnology a review. Allergy Proc 1990; 11(5): 197-208.

  16. Tabar AI, Garcia BE. A prospective safety monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993; 48(6): 450-3.

  17. Pacor ML, Biasi D. Currents trends in the specific immunotherapy for allergic syndromes due to Dermatophagoides pteronyssinus. 1994; 85(5): 285-8.

  18. Des Roches A, Paradis L. Immunotheraphy with a standardized Dermatophagoides pteronyssinus extract VI specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99(4): 450-3.

  19. Weber RW. Immunotherapy with allergens. JAMA 1997 10; 278(22): 1881-7.




2020     |     www.medigraphic.com